Dickran Kazandjian, MD
2 clinical trials · Sponsor
◉ Watch Dickran Kazandjian, MD
| Record | Firm | Date |
|---|---|---|
| Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse (NCT06910124) | Dickran Kazandjian, MD | 2025-12-02 |
| IMMUNOPLANT for Newly Diagnosed Multiple Myeloma (NCT06376526) | Dickran Kazandjian, MD | 2024-08-21 |
Track Dickran Kazandjian, MD automatically
Every clearance here is in the API, with alerts when new ones post.